Skip to main content
. 2012 Mar 22;23(8):859–870. doi: 10.1089/hum.2011.123

FIG. 3.

FIG. 3.

TK gene therapy increases survival rate and reduces infarct size. (A) Representative immunohistochemistry photographs of transgenic hTK protein expression in the infarcted region of mouse hearts at 3 and 7 days after MI. A variable amount of immunoreactive hTK is observed in Ad.hTK-injected groups. Rabbit IgG was substituted for primary antibodies as negative control. Original magnification: 200×. (B) Representative Masson's trichrome staining. Original magnification: 10×. Significantly reduced scar area in the Ad.hTK-treated hearts was observed 7 days after MI compared with the Ad.Null group. (C) Representative M-mode images at the level of papillary muscles. (D) A survival analysis was performed for the Ad.Null- (n=12) and Ad.hTK-treated (n=12) mice after MI. TK treatment increased survival rate compared with the Ad.Null group 7 days after MI. *p<0.01 vs. MI/Ad.Null.